Viewing nowPregabalin Capsule 75mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
CTC Bio Co., Ltd.

MFDS item code 201702685 · Approved 2017.05.29 · Insurance code 669502190
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, and treatment of fibromyalgia
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in epilepsy patients, with or without accompanying secondary generalized symptoms. Additionally, it is effective in the treatment of fibromyalgia, helping to alleviate pain and improve quality of life.
This medicine should be administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with renal impairment.”) Peripheral neuropathic pain — Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. Central neuropathic pain — Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to “4. Discontinuation of treatment.”) Epilepsy — Adults: The recommended starting dose is 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. After systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose is an additional dose administered as a single dose. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behavior, so it is important to carefully monitor for signs of depression, mood changes, or unusual behavior during treatment. This medication should not be administered to patients with hypersensitivity to it or with specific genetic problems, such as lactose intolerance. For diabetic patients, caution is needed as weight gain could necessitate dosage adjustments for blood glucose control medications. If allergic reactions such as angioedema occur, dosing should be discontinued immediately and a medical consultation is advised. Elderly patients are at risk for symptoms such as dizziness, drowsiness, and confusion, especially during initial doses. Transient visual disturbances or changes in vision have been reported, and medical advice should be sought if these symptoms occur. Abruptly discontinuing this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety; therefore, dosage should be tapered gradually under the guidance of a healthcare provider. Due to the risk of drug abuse, extra caution is necessary for patients with a history of substance misuse. Patients with impaired kidney function may require dosage adjustments, and those with cardiovascular diseases should be treated cautiously. Concomitant use with opioid analgesics may increase the risk of central nervous system depression. During early pregnancy, there is a risk of fetal malformation; thus, women of childbearing potential should employ effective contraception and avoid use during pregnancy. Breastfeeding women should consult healthcare providers regarding the discontinuation of either breastfeeding or the medication, as it may be passed to breast milk. Activities requiring alertness, such as driving or operating machinery, should be avoided while experiencing dizziness or drowsiness after taking this medication. Severe skin reactions can rarely occur; if symptoms such as skin rash or redness appear, dosing should be stopped immediately and a healthcare facility should be visited. In cases of overdose, symptoms may include drowsiness, confusion, and depression; emergency interventions like hemodialysis may be necessary if required. Keep out of reach of children and do not transfer to another container for safety.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like symptoms, restlessness, depression, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependence, weight gain, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, directional impairment, irritability, depression, euphoric feelings, decreased libido, insomnia, depersonalization, sexual arousal disorder, restlessness, anxiety, mood swings, emotional low, emotional high, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, dizziness, drowsiness, ataxia, motor coordination abnormalities, balance impairment, amnesia, attention disorder, memory impairment, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, hypersomnia, cognitive impairment, nystagmus, speech disorder, clonic contractions, decreased reflexes, abnormal movements, psychomotor agitation, positional dizziness, sensory hyperesthesia, burning sensation, activity tremor, fainting, confusion, motor retardation, olfactory abnormalities, taste loss, writing difficulties, blurred vision, diplopia, loss of indirect vision, visual disturbances, visual field deficits, photophobia, dry eyes, ocular swelling, decreased vision, eye pain, eye fatigue, increased tear production, ocular irritation, mydriasis, changes in depth perception during vibration, strabismus, visual brightness, vertigo, auditory hyperesthesia, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, shortness of breath, nasal hemorrhage, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, flatulence, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, joint pain, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle twitching, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling of intoxication, paresthesia, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hyperreactivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorder, drowsiness, confused state, agitation, restlessness, worsening of convulsions, ataxia, speech disorder, blood in stool, increased BUN, tinnitus, skin disorders
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect from air and moisture. It is advisable to keep it at room temperature between 15 and 30 degrees Celsius.
Hard capsule with the upper brown color and white lower part containing white powder.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
CTC Bio Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.